Skip to content
The Kids Research Institute Australia logo
Donate

Search

Research

Developing a human challenge model of GAS infection

NHMRC funding has been awarded for 4 years to Murdoch Childrens Research Institute for this project, with collaboration from Professor Jonathan Carapetis at The Kids.

Research

END RHD Community Project - Kimberley (Rheumatic Fever Strategy)

Kimberley Aboriginal Medical Services, Nirrumbuk Environmental Health and Services and The Kids Research Institute Australia seek to implement and evaluate a community-led project, funded by the Department of Health, to prevent and manage RHD in a selected high-risk Aboriginal community

Research

END RHD Demonstration Communities

The END RHD Communities approach uses community-led, research-backed prevention strategies to tackle Strep A skin and throat infections, acute rheumatic fever and rheumatic heart disease

Research

Improving delivery of secondary prophylaxis for rheumatic heart disease

Continued progress in controlling RHD requires an understanding of how to improve delivery of regular injections of penicillin - secondary prophylaxis (SP).

Research

Penicillin Levels for Rheumatic Heart Disease Study - WA Urban Cohort

This is a 6 month cohort study involving participants at Princess Margaret Hospital prescribed BPG for secondary prophylaxis of RHD.

Research

RHD Action

RHD Action is the name given to the global movement to reduce the burden of rheumatic heart disease (RHD) in vulnerable populations of all ages throughout the world.

Research

Strep A Vaccine Global Consortium (SAVAC) 1.0

The Kids Research Institute Australia (Jonathan Carapetis) is a member of the new Global Strep A Vaccine Consortium; a global GAS vaccine consortium that will drive strategic planning to anticipate requirements for licensure, prequalification, and policy recommendations.

Research

Strep A Vaccine Global Consortium (SAVAC) 2.0

The mission of SAVAC, the Strep A Vaccine Global Consortium, to ensure that safe, effective and affordable Strep A vaccines are available and implemented to decrease the burden of Strep A disease in the most in need.

Research

Excess Mortality Among People With Rheumatic Heart Disease in Australia

Jonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@

Research

Modeling the potential health impact of prospective Strep A vaccines

The World Health Organization published the preferred product characteristics for a Group A Streptococcus (Strep A) vaccine in 2018. Based on these parameters for the age of vaccination, vaccine efficacy, duration of protection from vaccine-derived immunity, and vaccination coverage, we developed a static cohort model to estimate the projected health impact of Strep A vaccination at the global, regional, and national levels and by country-income category.